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Sex Med 2Introduction: Low-intensity shockwave therapy (LISWT) has recently emerged as a promising method in the
treatment of erectile dysfunction (ED).
Aim: To assess the long-term results of the effectiveness and safety of LISWT in patients with ED who are
non-responders to phosphodiesterase type 5 inhibitor (PDE5i) treatment.
Methods: This open-label, longitudinal, and observational study investigated an uncontrolled population of 50
consecutive patients whose ED was unresponsive to PDE5i treatment. Patients were treated with a four-session
LISWT protocol. During active treatment and follow-up, all patients remained on their regular high on-demand
or once-daily PDE5i dosing schedules.
Main Outcome Measures: Effectiveness was assessed according to the International Index of Erectile Function
erectile function domain, questions 2 and 3 of the Sexual Encounter Proﬁle, Erection Hardness Scale, and Global
Assessment Question scores at baseline and at 3, 6, 9, and 12 months after treatment. Patients were considered
responders whenever they showed improvement in erection parameters in all four assessments and responded
positively to the Global Assessment Question. Adverse events were recorded. Statistical variables were applied and
ﬁndings were considered statistically signiﬁcant at a P value less than < .05.
Results: Eighty percent (mean age¼ 64.8 years) completed the 12-month follow-up. Positive response rates were
60% of available subjects at the end of the study and 48% of the intent-to-treat population. After the 12-month
follow-up, 91.7% of responders maintained their responses. No patient reported treatment-related adverse events.
Conclusion: LISWT in patients with ED unresponsive to PDE5i treatment was effective and safe in 60% of
patients treated. The efﬁcacy response was maintained for 12 months in most patients.
Sex Med 2016;4:e225ee232. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the Inter-
national Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Erectile dysfunction (ED) is a medical entity that is highly
prevalent in men older than 50 years whose history of vascular
risk factors (VRFs) has been a common denominator in the
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016;4:e225ee232Many studies have stressed the status of ED as a potential
indicator of cardiovascular disease, although other clinical trials
have found a high incidence of ED in men with VRFs such as
metabolic syndrome, diabetes, and hypertension.2,3
Since 1998, the phosphodiesterase type 5 inhibitor (PDE5i)
has introduced a change in the treatment paradigm for patients
with ED because approximately 60% of patients can recover
their erectile function and lead a satisfactory sex life.4
Despite the effectiveness of PDE5i in the treatment of ED,
40% to 50% of patients—depending on the etiology of the
dysfunction—do not respond to this drug therapy, even after
optimization approaches such as treatment combinations have
been implemented.5e10e225
e226 Bechara et alFor some years, low-intensity shockwave therapy (LISWT) has
been implemented for the treatment of ED and to optimize the
response to PDE5i.
A shockwave is a wave of abrupt pressure (vibration move-
ment) produced by an object that travels faster than the speed of
sound (<10 ns) producing external pressure differences and
increased temperature.11
Since the 1980s, shockwaves of different intensities have been
used therapeutically in medicine. High-intensity shockwaves
(pressure ¼ 450 bar) have been implemented in the treatment of
urolithiasis, medium-intensity shockwaves (pressure ¼ 200 bar)
in the treatment of arthralgia, tendinitis, and bursitis, and more
recently LISWT (pressure ¼ 80 bar) in the treatment of ED.
Young and Dyson12 discovered that therapeutic ultrasound
encourages angiogenesis by enhancing the expression of vascular
endothelial growth factor. Nurzynska et al13 reported that
shockwaves have a positive inﬂuence on the proliferation and
differentiation of cardiomyocytes, smooth muscle, and endo-
thelial cell precursors, with a more obvious effect in cells from a
normal heart than from a pathologic heart.
After these initial reports, LISWT was implemented in the
treatment of chronic myocardial ischemia and diabetic foot
ulcers, among other applications.14e18
The idea of applying LISWT to the penis stemmed from a
study with animals that proved that the energy of shockwaves
applied to the myocardium of pigs ameliorates ischemia-induced
myocardial dysfunction.14 By extrapolating these ﬁndings to ED,
it was presumed that shockwaves applied to the penis might
increase blood ﬂow and improve endothelial function through
the stimulation of angiogenesis in the corpus cavernosum.
The mechanism of action is still not completely elucidated.
However, low-intensity energy has been shown to induce the
production of a physiologically signiﬁcant amount of
non-enzymatic nitric oxide and activate intracellular cascade
pathways that trigger the release of angiogenic factors.19
In this way, shockwaves produce mechanic stress and micro-
trauma at the cellular level, thus generating a series of biological
cascades that favor the release of angiogenic factors leading to
neovascularization.
In vivo and in vitro evidences have proved that shockwaves
enhance the expression of growth factors related to angiogenesis,
increase mRNA and vascular endothelial growth factor cellular
levels and its receptor, Flt-1, induce neovascularization, increase
blood supply, and signiﬁcantly increase angiogenic markers.14e17
In that regard, Qiu et al20 found that shockwave therapy
signiﬁcantly restored erectile function in rats with streptozotocin-
induced diabetes mellitus to levels similar to those exhibited by
healthy controls, thus validating the animal model as comparable
to prior clinical trials performed in humans. According to trial
results, improvements in erectile function might be attributable to
the positive effects afforded by the shockwaves on endothelial andsmoothmuscle regeneration in the penis. These effects appear to be
mediated by the recruitment of endogenous smooth muscle cells.
Interestingly, the results recently published by Assaly-
Kaddoum et al21 showed that LISWT signiﬁcantly improved
erectile function in Goto-Kakizaki rats to the same extent as
sildenaﬁl. Furthermore, the effects of LISWT were potentiated
with sildenaﬁl. Nevertheless, this was not mediated by a
mechanism dependent on nitric oxide and cyclic guanosine
monophosphate and the investigators encouraged further
investigation of the mechanism of action of these devices.
The ﬁrst observation studies in patients who responded poorly
to PDE5i therapy reported on the efﬁcacy and safety of LISWT
devices, especially in patients with ED of vascular origin and in
those with a poor response to PDE5i treatment.22,23
Recently, Kitrey et al24 performed a sham-controlled evaluation
of penile LISWT effect in 58 patients unable to achieve sexual
intercourse using a PDE5i. In the LISWT and sham groups,
54.1% and 0% of patients, respectively, achieved an erection hard
enough for vaginal penetration. According to changes in the
International Index of Erectile Function erectile function domain
(IIEF-EF) score, treatment was effective in 40.5% of men who
received LISWT but in none in the sham group.AIM
Based on these ﬁndings, the aim of this study was to assess the
effectiveness and safety of LISWT after 12 months in the
treatment of ED in patients with a history of vascular disease or
associated VRFs with a low response to PDE5i treatment.METHODS
This study was an open-label, longitudinal, observational, and
independent study designed to evaluate the safety and efﬁcacy of
LISWT in an uncontrolled population of sexually active men
with ED unresponsive to PDE5i treatment and associated VRFs.
This study consisted of a screening phase, a treatment phase,
and a 12-month follow-up phase. At the screening phase,
patients had an extensive medical and sexological history evalu-
ation and a physical examination.
The inclusion criteria involved sexually active men with ED
that was unresponsive to PDE5i treatment and exhibited VRFs
(eg, diabetes, hypertension, dyslipidemia, and coronary artery
disease). Patients with untreated hypogonadism or a history of
pelvic surgery and patients with ED of neurologic origin
(resulting from prostatectomy, pelvic surgery, or spinal cord
injury) were excluded.
Patients were considered non-responders to PDE5i if they,
after completing all optimization measures commonly suggested
(correct dose optimization of PDE5i, correction of risk factors,
improvement in sexual stimuli, correction of testosterone levels,
and proper patient dietary training, especially with the use ofSex Med 2016;4:e225ee232
Figure 1. Study ﬂowchart. EHS ¼ Erection Hardness Scale; GAQ ¼ Global Assessment Question; IIEF-EF ¼ International Index of
Erectile Function erectile function domain; LISWT ¼ low-intensity shockwave therapy; SEP2 and 3 ¼ questions 2 and 3 of Sexual
Encounter Proﬁle.
LISWT for ED Unresponsive to PDE5 Inhibitors e227short-acting PDE5i), had an IIEF-EF score lower than 26 points
when using these drugs.10,11
Fifty consecutive patients with ED fulﬁlled the inclusion
criteria and accepted the invitation to participate. During
LISWT and follow-up, these patients continued with PDE5i
treatment at the maximum dose or with a daily dose under the
same treatment protocol. Only those patients who completed the
12-month follow-up were considered for result analysis.
Severity of ED was classiﬁed into ﬁve categories according to
the IIEF-EF score.25
The following evaluation criteria were used: IIEF-EF to assess
ED severity, questions 2 and 3 from the Sexual Encounter Proﬁle
(SEP2 and SEP3) to assess penetration and erection sustain-
ability, the Erection Hardness Score (EHS), and a Global
Assessment Question (GAQ): Has the treatment improved the
quality of your erections?26e29
Improvement of the IIEF-EF score was deﬁned as an increase
from baseline to follow-up (12 months after treatment)
according to the minimal clinically differences suggested by
Rosen et al.30
The criterion for treatment success according to the EHS was
a score of 3 or 4. Assessment measurements were taken face to
face before treatment and 3, 6, 9, and 12 months after LISWT
completion (Figure 1).
Patients were considered responders to LISWT whenever they
showed improvement in erection parameters in all four assess-
ments (IIEF-EF, SEP2, SEP3, and EHS) and responded
positively to the GAQ at 3, 6, 9, and 12 months after treatment.
Adverse events were recorded.
This trial was performed using Renova, an extracorporeal
LISWT device (Direx Argentina, Buenos Aires, Argentina). This
equipment uses linear shockwaves and, unlike previous models,
spans the entire area of the organ (up to 70 mm) and thus can
apply shockwaves with greater precision at the penile crura and
corpus cavernosum.31Sex Med 2016;4:e225ee232The subjects started the treatment right after inclusion in the
study because they continued their respective current PDE5i
therapies.
According to previously published studies, the treatment
consisted of applying 14,400 shockwaves during a period of 4
weeks. In each session, the patient received 3,600 shockwaves of
0.09 mJ/mm2: 1,800 were applied to the penis (900 to each
corpus cavernosum) and 1,800 were applied to the perineum
(900 to each crus). The areas that received treatment were the
same at each session. All sessions were performed without
anesthesia in an outpatient setting and each lasted 20 minutes.31
The study was conducted according to Good Clinical Practices
and the Declaration of Helsinki, it was approved by the local
research ethics committee, and all patients signed an informed
consent form.
Variables of demographic characteristics of responders and non-
responderswere calculatedusing theMann-Whitney test andFisher
exact test. Efﬁcacy variables were assessed using the Friedman test,
and individual comparisons were assessed with the Bonferroni-
Dunn method. Statistical variables were applied and ﬁndings
were considered statistically signiﬁcant at a P value less than .05.Main Outcome Measures
Effectiveness was assessed using the IIEF-EF, SEP2 and SEP3
diaries, EHS, and GAQ at baseline and at 3, 6, 9, and 12 months
after treatment.RESULTS
Eighty percent of patients (40 of 50) completed the treatment
and 12-month follow-up. Ten patients with similar demographic
characteristics were excluded from the study because of loss to
the ﬁrst follow-up.
Median age was 64.8 years and duration of ED was 70.5
months.
Table 1. Demographic characteristics of patients (responders and non-responders to low-intensity shockwave therapy)
Responders (n ¼ 24) Non-responders (n ¼ 16) P value
Age (y), mean (range) 65 (50e82) 64.4 (48e82) .8902*
Duration of ED (mo) 64.4 77.8 .4385*
Range (mo) 12e132 8e120
Vascular risk factors, n (%)
Hypertension 14 (58.3) 11 (68.8) .7397†
Diabetes mellitus 3 (12.5) 7 (43.8) .0588†
Dyslipidemia 11 (45.8) 9 (56.3) .7475†
Coronary artery disease 10 (41.7) 7 (43.8) .9999†
Severity of ED according to IIEF, n (%)
Severe 4 (16.7) 6 (37.5) .1592†
Moderate 12 (50) 4 (25) .1881†
Mild to moderate 4 (16.7) 4 (25) .6905†
Mild 4 (16.7) 2 (12.5) .9999†
ED ¼ erectile dysfunction; IIEF ¼ International index of Erectile Dysfunction.
*Mann-Whitney test.
†Fisher exact test.
e228 Bechara et alThe positive response rate was 60% of available subjects at the
end of the study and 48% of the intent-to-treat population.
Sixty percent of patients (24 of 40) showed improvement in
efﬁcacy parameters in all four assessments (IIEF-EF, SEP2,
SEP3, and EHS) and responded positively to the GAQ. These
changes were signiﬁcant from the ﬁrst follow-up (3 months after
treatment).
By the third month after treatment, 91.7% of responders to
LISWT (22 of 24) maintained efﬁcacy parameters up to the last
follow-up visit 12 months after treatment.
No statistically signiﬁcant difference was found for age,
duration of ED, comorbidities, and dysfunction severity when
comparing responders to LISWT (24 of 40) with non-responders
to LISWT (16 of 40; Table 1).
In responders to LISWT, the increase in results obtained
through the IIEF-EF score was statistically signiﬁcant from the
3-month assessment after treatment, reaching a mean of 9.3
points and of 9.1 points by 12 months after treatment (Figure 2).
From 3 months after treatment to the end of follow-up
monitoring, signiﬁcant changes were encountered in the
responder group for the EHS and SEP2 and SEP3, with a
response rate of almost 80% of attempts (Figure 2).
Improvements in the IIEF-EF score were higher whenever ED
was more severe, with changes of 13, 10.5, 6.8, and 4.5 points
for patients with severe, moderate, mild to moderate, and mild
ED, respectively (Table 2).
Thirteen patients reached a score of at least 26 points in the
IIEF-EF score, and the degree of severity decreased in nine and
remained unchanged in two.
DISCUSSION
This study evaluated a group of patients with ED and
associated VFRs who responded poorly to PDE5i therapy in a12-month pilot study. Erectile function was recovered in 60% of
patients after treatment with linear-focused LISWT.
Most randomized, double-blinded, sham-control trials have
reported the efﬁcacy of LISWT in patients with ED.32e34
Vardi et al32 presented the ﬁrst randomized, double-blinded,
sham-control trial that demonstrated that LISWT had a posi-
tive short-term clinical and physiologic effect on the erectile
function of men who respond to oral PDE5i therapy. They
found a signiﬁcantly greater increase in the IIEF-EF score in the
treated group than in the sham-treated group. In addition,
physiologic penile hemodynamic signiﬁcantly improved in the
treated group but not in the sham group (maximal postischemic
penile blood ﬂow ¼ 8.2 vs 0.1 mL/[min $ dL], P < .0001)
assessed using plethysmography.
However, Yee et al,33 using a similar treatment scheme to the
one used in the study by Vardi et al32 and implementing the
same shockwave therapy system (Omnispec ED1000; Medispec
Ltd, Germantown, MD, USA), did not ﬁnd signiﬁcant statistical
evidence in the IIEF score and EHS score in a group of 28
patients under LISWT treatment compared with a sham-treated
group of 30 patients. Nevertheless, they found a signiﬁcant
difference in patients with severe ED according to the Sexual
Health Inventory for Men and concluded that LISWT has
clinical efﬁcacy in this subgroup of patients.
More recently, Srini et al,34 in a randomized double-blinded trial
with active treatment and sham therapy, reported a positive long-
term efﬁcacy in patients with vasculogenic ED treated with linear-
focused shockwaves, just as Vardi et al32 had (Omnispec ED1000).
In a narrative review of all published studies, Gruenwald
et al35 found that 60% to 75% of treated patients who responded
to PDE5i therapy could eliminate their dependency on those
drugs and achieve an erection and vaginal penetration and that
72% of non-responders to PDE5i before undergoing LISWT
became responders and achieved vaginal penetration.Sex Med 2016;4:e225ee232
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Figure 2. Evolution of changes in IIEF-EF score, SEP2, and SEP3 in responders to LISWT (n ¼ 24). P < 0.05 by Friedman test (*baseline
vs **Fup 3, vs ***Fup 6, vs ****Fup 9, vs *****Fup 12). Fup 3 ¼ 3-month follow-up; Fup 6 ¼ 6-month follow-up; Fup 9 ¼ 9-month follow-up;
Fup 12 ¼ 12-month follow-up; IIEF-EF ¼ International Index of Erectile Function erectile function domain; SEP2 and 3 ¼ questions 2 and 3
of the Sexual Encounter Proﬁle.
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ﬁtted with a targeted shockwave source (Omnispec ED1000).
Unlike the system used for the present patients, Gruenwald et al35
had to stretch the penis and manually apply the transducer to itTable 2. IIEF-6 changes according to severity of ED before and 12 m
ED severity n
Baseline IIEF-6 score,
mean ± SD
Follow
mean
Severe 4 9 ± 1.155 22 ±
Moderate 12 12.8 ± 1.328 23.3 ±
Mild to moderate 4 18.5 ± 1.291 25.3 ±
Mild 4 22.8 ± 0.500 26.3 ±
Total 24 14.7 ± 4.757 23.9 ±
ED ¼ erectile dysfunction; IIEF-6 ¼ International index of Erectile Dysfunction.
Sex Med 2016;4:e225ee232proximally, medially, and distally and then apply it to the peri-
neum. With this operator-dependent method, the selected treat-
ment protocol consisted of two sessions per week for a period of 3
weeks and was repeated after a treatment-free interval of 3 weeks.onths after treatment with shockwaves of low intensity
-up 12-mo IIEF-6 score,
± SD
IIEF-6 improvement
points P value
3.651 13 .029
4.619 10.9 .0001
4.113 6.8 .002
4.193 4.5 .3429
4.303 9.2 .0001
e230 Bechara et alChung and Cartmill,36 in an open-label prospective study of
30 patients with ED, assessed the efﬁcacy and safety of an
electromagnetic shockwave unit of higher energy density (0.25
mJ/mm2) previously used in the treatment of tenosynovitis and
tendinitis (Duolith SD1 Ultra; Storz Medical AG, Tägerwilen,
Switzerland). Treatment duration consisted of two sessions per
week for a period of 6 uninterrupted weeks. Sixty percent of
patients showed an improved erectile response according to the
IIEF-5 and the Erectile Dysfunction Inventory of Treatment
Satisfaction index 6 weeks after treatment, and this effect
remained for 4 months.
The present trial was performed using the Renova NR. Its
design makes it operator independent: its transducer can deliver
shockwaves after being secured to the penis and the perineum;
thus, the operator does not need to hold the device. The trans-
ducer spans an area of 70 mm, which allows effective application
to each corpus cavernosum. LISWT involves a very small
amount of energy (0.09 mJ/mm2), equivalent to 10% of the
energy used by conventional lithotripters for the treatment of
urinary tract stones.
The efﬁcacy of the Renova NR reported by other investigators
was an average improvement of more than four points in the
IIEF-EF score, thus going beyond the minimal important dif-
ferences proposed by Rosen et al30 to consider a treatment of ED
effective.
Reisman et al,31 in a multicenter study with a larger number of
patients and 6-month follow-up, reported 81% efﬁcacy, whereas
Ruffo et al37 reported 76% efﬁcacy in a group of 31 patients and
3-month follow up.
Currently, no available study has directly compared the
efﬁcacy of these three different LISWT methods. In the present
study, improvements in IIEF-EF, SEP2, SEP3, and EHS scores
became evident from the ﬁrst through the third follow-ups after
treatment, with statistically signiﬁcant values that were main-
tained to the end of the follow-up phase in 90% of patients.
It is worth pointing out that, unlike what has been reported
by other investigators, the present study considered a patient
responsive to LISWT when he showed improvement in efﬁ-
cacy in all four assessments and responded positively to the
GAQ and not just the IIEF score alone, which reinforces the
result of this study. It is well known that changes in IIEF
imply only an improvement in score but does not necessarily
guarantee a patient’s successful or complete sexual intercourse.
In contrast, many men consult for the correction of erections
insufﬁcient for penetration, yet they are not fully satisﬁed.
Sixty percent of the present patients achieved and maintained
an erection after penetration, and they were satisﬁed with the
improvement of their penile rigidity after treatment.
This might better explain the lower efﬁcacy compared with
other studies.
Factors such as patient age and duration of ED did not
inﬂuence the results.An interesting aspect to consider is that patients continued
their regular treatment and PDE5i drug throughout LISWT,
thus eliminating the resulting bias of suspending and resuming
oral treatment as described in other trials. Therefore, each patient
was compared with himself before and after shockwave therapy
concurrently with PDE5i treatment.
This study has several limitations that are important to
consider. First, its lack of a placebo group prevents a proper
comparison of the effects of LIWST. As mentioned earlier,
other trials have shown signiﬁcant differences between active
and placebo treatments.24,32e34 Second, this research extended
through a follow-up period of 12 months and sustained the
patients’ response; thus, there was no placebo treatment,
which tends to be brief and not sustained over time, although
this aspect has not been fully elucidated. Third, 10 patients
were not included in the results owing to lack of follow-up. If
one assumes that those 10 patients dropped out because of lack
of response or were disappointed with the results, then this
could constitute a serious bias when interpreting the results. If
this were the case, then the response rate would be of 48%
instead of 60%. This value seems more realistic given the
weight of the results presented by Kitrey et al24 who obtained
approximately 50% recovery in non-responders to PDE5i
therapy in a prospective, randomized, double-blinded, sham-
controlled study. If the lack of placebo is considered an
important bias, then it should be considered representative of a
“real-life” setting.
In contrast, whenever independent pilot studies are conduct-
ed, the number of patients included tends to be small, and the
results cannot be generalized. Nevertheless, however limited the
data and the experiences reported in the literature thus far, one
can consider these data quite promising.
There is no certainty that these improvements were due to the
vascular changes suggested by other investigators because this
study had an observational design of clinical practice; patients did
not undergo any penile vascular study such as a Doppler evalu-
ation that can show changes in the cavernosal arteries.
There are many uncertainties to LISWT: the published liter-
ature is not multicentric and usually has a small number of
patients and short follow-up time. It is not clear whether the
number of sessions and treatments was sufﬁcient. It does not
deﬁne the best proﬁle of patients who might beneﬁt from this
treatment. The mechanism of action is not clear.
Nevertheless, LISWT has a good safety proﬁle, with no
adverse events reported. The effectiveness in clinical and
empirical practice is high. This new treatment modality seems
promising to optimize treatments of ED, especially in patients
with associated VRFs.
The main contribution of this study is adding more data using
LISWT with only four sessions and a second-generation device
in patients with ED unresponsive to PDE5i and associated VRFs
followed for 1 year.Sex Med 2016;4:e225ee232
LISWT for ED Unresponsive to PDE5 Inhibitors e231Despite the enthusiasm over these results, it is necessary to
have a larger number of long-term multicentric placebo-
controlled studies that can prove the efﬁcacy and safety of this
innovative treatment tool, thus avoiding false expectations and
unnecessary medical expenses.CONCLUSIONS
Extracorporeal LISWT in patients with ED unresponsive to
PDE5i treatment was effective and safe in 60% of patients. The
efﬁcacy response was maintained for 12 months in most patients.
Large-scale, multicentric, long-term, randomized, sham-
controlled studies are needed to determine the beneﬁts of this
new line of treatment for ED.Corresponding Author: Amado Bechara, MD, PhD, Instituto
Medico Especializado, Hidalgo 568, Buenos Aires 1405, Argentina.
Tel: 541-149-039-777; Fax: 541-149-039-777; E-mail: amado-
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